An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial.

Autor:	Chaker, A. M.1 adam.chaker@tum.de, Al-Kadah, B.2, Luther, U.3, Neumann, U.4, Wagenmann, M.5
Zdroj:	Clinical & Translational Allergy. 2/2/2016, Vol. 6, p1-7. 7p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu